CPLX2 and breast carcinoma: We also found significant decreases of CPLX2, which is decreased during the progression of oesophageal tumours [58] and decreased in association with lymphatic invasion in neuroendocrine lung tumours [59], and KCND3 whose levels decrease in association with increased breast cancer stage [60] in VIVA1 cells compared to the parental MDA-MB-134VI cell line.